Aldeyra Therapeutics, Inc. (ALDX)
Market Cap | 473.03M |
Revenue (ttm) | n/a |
Net Income (ttm) | -39.42M |
Shares Out | 37.80M |
EPS (ttm) | -1.26 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | January 15 |
Last Price | $13.37 |
Previous Close | $12.19 |
Change ($) | 1.19 |
Change (%) | 9.73% |
Day's Open | 12.36 |
Day's Range | 12.31 - 13.60 |
Day's Volume | 3,349,744 |
52-Week Range | 1.62 - 13.60 |
The company announced the pricing of a public stock offering.
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced positive top-line symptom, redness, and Schirmer's test results from the run-in cohort of...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, January 7, 2021, to discuss top-line sy...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced confirmation of SARS-CoV-2 antiviral activity of ADX-1612, in addition to novel anti-infl...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the initiation of Phase 2 clinical trials of ADX-629, a first-in-class orally administere...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the company's senior management will participate in the following virtual investor c...
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2020 Results - Quick Version Earnings Call Transcript
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and CEO Todd C. Brady, M.D., Ph.D., will discuss Aldeyra's novel therapeut...
Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX), a company focusing on immune-mediated diseases, are primed for further upside, according to a Jefferies analyst. The Aldeyra Analyst: Kelly ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it will present new data from the Phase 2 allergen chamber clinical trial of reproxa...
Is (ALDX) Outperforming Other Medical Stocks This Year?
4 Small Drug Stocks to Look Out For Amid Coronavirus Uncertainty
Is (ALDX) Outperforming Other Medical Stocks This Year?
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics: A New Cure To A Serious 21st Century Problem
Week 35 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
Aldeyra Therapeutics, Inc. (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2020 Results - Earnings Call Transcript
Aldeyra (ALDX) reports narrower-than-expected loss in the second quarter of 2020.
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.
Aldeyra's (ALDX) pipeline progress will be in focus when it reports Q2 results later in the week.
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of pati...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will discuss the ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential ...
Aldeyra Therapeutics, Inc. (ALDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
Aldeyra's Reproxalap Progress And Other News: The Good, Bad And Ugly Of Biopharma
Aldeyra Therapeutics' (ALDX) CEO Todd Brady on COVID-19 Development Update Conference Call - Transcript
Shares of Kindred Biosciences and Vaxart popped Wednesday after the drugmakers inked a manufacturing deal for a coronavirus vaccine tablet. Aldeyra is also planning to test a treatment.
Aldeyra (ALDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for May 14th
Aldeyra Therapeutics Inc (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
As of late, it has definitely been a great time to be an investor in Aldeyra Therapeutics.
Aldeyra Therapeutics, Inc. (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q4 2019 Results - Earnings Call Transcript
Aldeyra Therapeutics Inc. shares ALDX, -6.14% rose more than 13% in premarket trade Tuesday before surrendering their gains, after the biotech reported positive results in the first part of a ...
Aldeyra Therapeutics Continues To Make Progress In Big Potential Markets Despite Stock Weakness
About ALDX
Aldeyra Therapeutics, a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, a sight-threatening retinal disease. The company's portfolio also consists of ADX-1612, a small m... [Read more...]
Industry Biotechnology | IPO Date May 2, 2014 |
CEO Dr. Todd C. Brady M.D., Ph.D. | Employees 11 |
Stock Exchange NASDAQ | Ticker Symbol ALDX |
Analyst Forecasts
According to 8 analysts, the average rating for ALDX stock is "Strong Buy." The 12-month stock price forecast is 26.60, which is an increase of 98.95% from the latest price.